Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a tertiary hospital

Journal of Medical Virology

Volumn 81, Issue 3, 2009, Pages 406-412

  Lukhwareni, Azwidowi ^a   Burnett, Rosemary J ^a   Selabe, S Gloria ^a   Mzileni, M Olga ^a   Mphahlele, M Jeffrey ^a  

^a UNIVERSITY OF LIMPOPO   (South Africa)

Author keywords

HBV HIV co infection; Hepatitis B virus; Human immunodeficiency virus; Sub Saharan Africa

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA; HEPATITIS B ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; POLYMERASE CHAIN REACTION; PREVALENCE; SEROPREVALENCE; SOUTH AFRICA; TERTIARY HEALTH CARE; VIREMIA; VIRUS DETECTION; BLOOD; COMORBIDITY; HOSPITAL; ISOLATION AND PURIFICATION; METHODOLOGY; RETROSPECTIVE STUDY; VIROLOGY; VIRUS LOAD;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; COMORBIDITY; DNA, VIRAL; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HOSPITALS; HUMANS; POLYMERASE CHAIN REACTION; PREVALENCE; RETROSPECTIVE STUDIES; SOUTH AFRICA; VIRAL LOAD;

EID: 60049093148     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21418     Document Type: Article

References (31)

1. Alberti A, Clumeck N, Collins S. 2005. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 42:615-624.
2. Avettand-Fenoel V, Thabut D, Katlama C, Poynard T, Thibault V. 2006. Immune suppression as the etiology of failure to detect anti-HBc antibodies in patients with chronic hepatitis B virus infection. J Clin Microbiol 44:2250-2253.
3. Basaras M, Santamaria A, Sarsa M, Gutiérrez E, De Olano Y, Cisterna R. 1999. Seroprevalence of hepatitis B and C, and human immunodeficiency type 1 viruses in a rural population from the Republic of Equatorial Guinea. Trans R Soc Trop Med Hyg 93:250-252.
4. Burnett RJ. 2008. Hepatitis B virus and human immunodeficiency virus co-infection: Impact on transmission and natural history of the disease. SAJEI 23:19-23.
5. Burnett RJ, François G, Kew MC, Leroux-Roels G, Meheus A, Hoosen AA, Mphahlele MJ. 2005. Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: A call for further investigation. Liver Int 25:201-213.
6. Burnett RJ, Ngobeni JM, François G, Hoosen AA, Leroux-Roels G, Meheus A, Mphahlele MJ. 2007. Increased exposure to hepatitis B virus infection in HIV-positive South African antenatal women. Int J STD AIDS 18:152-156.
7. Cooley L, Sasadeusz J. 2003. Clinical and virological aspects of hepatitis B co-infection in individuals infected with human immunodeficiency virus type-1. J Clin Virol 26:185-193.
8. Gilson RJ, Tedder RS, Weller IV. 1989. Hepatitis B: Reactivation or reinfection associated with HIV-1 infection. Lancet 2:1330.
9. Grob P, Jilg W, Bornhak H, Gerken G. 2000. Serological pattern "anti-HBc alone": Report on a workshop. J Med Virol 62:450-4455.
10. Hofer M, Joller-Jemelka HI, Grob PJ, Lüthy R, Opravil M. 1998. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 17:6-13.
11. Hoffmann CJ, Thio CL. 2007. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 7:402-409.
12. Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, Churchyard GJ, Chaisson RE, Grant AD. 2007. Hepatotoxicity in an African antiretroviral therapy cohort: The effect of tuberculosis and hepatitis B. AIDS 21:1301-1308.
13. Horvath J, Raffanti SP. 1994. Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. Clin Infect Dis 18:339-347.
14. Kashala O, Mubikayi L, Kayembe P, Mukeba P, Essex M. 1994. Hepatitis B virus activation among Central Africans infected with human immunodeficiency virus (HIV) type 1. J Infect Dis 169:628-632.
15. Kew MC. 1996. Progress towards the comprehensive control of hepatitis B in Africa: A view from South Africa. Gut 38:S31-S36.
16. Kiire CF. 1996. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: A view from tropical and subtropical Africa. Gut 38:S5-S12.
17. Lodenyo H, Schoub B, Ally R, Kairu S, Segal I. 2000. Hepatitis B and C virus infections and liver function in AIDS patients at Chris Hani Baragwanath Hospital, Johannesburg. East Afr Med J 77:13-15.
18. Mastroianni CM, Trinchieri V, Santopadre P, Licthner M, Forcina G, D'Agostino C, Corpolongo A, Vullo V. 1998. Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy. AIDS 12:1939-1940.
19. Modi AA, Feld JJ. 2007. Viral hepatitis and HIV in Africa. AIDS Rev 9:25-39.
20. Mphahlele MJ. 2008. Impact of HIV co-infection on hepatitis B prevention and control: A view from sub-Saharan Africa. SAJEI 23:14-18.
21. Mphahlele MJ, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. 2006. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 35:14-20.
22. Piroth L, Binquet C, Vergne M, Minello A, Livry C, Bour JB, Boisson M, Duong M, Grappin M, Portier H. 2002. The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol 36:681-686.
23. Pogany K, Zaaijer HL, Prins JM, Wit FW, Lange JM, Beld MG. 2005. Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients. AIDS Res Hum Retrovir 21:922-926.
24. Rogers AS, Lindsey JC, Futterman DC, Zimmer B, Abdalian SE, D'angelo LJ. 2000. Serologic examination of hepatitis B infection and immunization in HIV-positive youth and associated risks. The Pediatric AIDS Clinical Trials Group Protocol 220 Team. AIDS Patient Care STDS 14:651-657.
25. Salmon-Ceron D, Lewden C, Morlat P. 2005. Liver disease as a major cause of death among HIV infected patients: Role of hepatitis C and B viruses and alcohol. J Hepatol 42:799-895.
26. Selabe SG, Lukhwareni A, Song E, Leuw YG, Burnett RJ, Mphahlele MJ. 2007. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: Implications for antiretroviral therapy in HBV and HIV co-infected South African patients. J Med Virol 79:1650-1654.
27. Thio CL, Seaberg EC, Skolasky R, Jr. 2002. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360:1921-1926.
28. UNAIDS. 2007. AIDS epidemic update http://data.unaids.org/pub/ EPISlides/2007/2007-epiupdate-en.pdf.
29. Uneke CJ, Ogbu O, Inyama PU, Anyanwu GI, Njoku MO, Idoko JH. 2005.Prevalence of hepatitis-B surface antigen among blood donors and human. immunodeficiency virus-infected patients in Jos, Nigeria. Mem Inst Oswaldo Cruz 100:13-16.
30. Waite J, Gilson RJ, Weller IV, Lacey CJ, Hambling MH, Hawkins A, Briggs M, Tedder RS. 1988. Hepatitis B virus reactivation or re-infection associated with HIV-1 infection. AIDS 2:443-448.
31. Weiss J, Wu H, Farrenkopf B, Schultz T, Song G, Shah S, Siegel J. 2004. Real time TaqMan PCR detection and quantitation of HBV genotypes A-G with the use of an internal quantitation standard. J Clin Virol 30:86-93.